Gilead Sciences is set to join the T-cell engager space in an unusual – perhaps even unprecedented – deal arrangement that involves the pharma budgeting $1.675 billion upfront to buy Ouro Medicines and for Galapagos …
Otsuka buys Transcend Therapeutics for $700M upfront
Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide


